Last reviewed · How we verify
SPM 927
SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity.
SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity. Used for Epilepsy (focal seizures), Generalized seizures.
At a glance
| Generic name | SPM 927 |
|---|---|
| Sponsor | UCB Pharma |
| Drug class | T-type calcium channel blocker |
| Target | T-type calcium channel (Cav3.1, Cav3.2, Cav3.3) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
SPM 927 selectively inhibits T-type calcium channels, which are involved in the generation and propagation of seizures. By blocking these channels, the drug reduces abnormal neuronal firing and is being developed as an anti-seizure medication. T-type calcium channel blockade represents a distinct mechanism from many existing antiepileptic drugs.
Approved indications
- Epilepsy (focal seizures)
- Generalized seizures
Common side effects
- Dizziness
- Somnolence
- Fatigue
- Ataxia
Key clinical trials
- A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 (PHASE2)
- A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN). (PHASE2)
- An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy (PHASE2)
- A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy (PHASE3)
- A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 (PHASE3)
- Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures (PHASE3)
- Lacosamide in Preventing Seizures in Participants With Malignant Glioma (NA)
- Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPM 927 CI brief — competitive landscape report
- SPM 927 updates RSS · CI watch RSS
- UCB Pharma portfolio CI